Theravance Biopharma Inc. has just released results from their 2nd Phase 3 investigation of Ampreloxetine as a therapy for symptomatic neurogenic orthostatic hypotension (nOH). Symptomatic nOH NOH is a rare…
Lewy Body DementiaWhat is Lewy body dementia? Lewy body dementia is the second most common form of dementia, characterized by progressively declining mental ability. Affected individuals experience changes in memory, motor…
Earlier this year, 4D Pharma Plc. ("4D Pharma") experienced a "win" when the FDA approved the company's plans to initiate a Phase 1 clinical trial evaluating MRx0005 and MRx0029 for Parkinson's…
According to a recent article in NeurosScience News, one percent of individuals over the age of sixty are at risk for Parkinson’s disease. Patients are generally diagnosed at a late…
February 28, 2022 is celebrated annually as Rare Disease Day. This is a major event for the rare disease patient community that helps spread awareness and shine a light on…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Most people have heard of Viagra, and they know it as a treatment for erectile dysfunction (ED). Fewer people know it as Revatio, which is indicated for pulmonary arterial hypertension…
Cannabidiol (CBD) has been explored as a potential therapy for a variety of different conditions, ranging from various forms of epilepsy to dystonia to Parkinson's disease. Now, researchers are questioning…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
